johannes-ludwig-8dejZGw3Hec-unsplash.jpg

AOA Press Release

AOA Dx Featured in The Journal of Precision Medicine

January 10, 2022

AOA Dx Inc is proud to announce that they were featured in The Journal of Precision Medicine, titled “Tumor Glycolipids, a New Frontier for Early Detection and Precision Medicine in Ovarian Cancer and Other Malignancies”.  The paper was authored by AOA’s Chief Scientific Officer H. Uri Saragovi, PHD, AOA’s co-founder and Chief Business Officer Anna Milik Jeter and Samantha A. Yee, a PhD candidate at UT San Antonio.

"We are excited to present the early research on quantification of tumor marker gangliosides, a novel approach to early cancer detection. Ovarian cancer has the lowest 5-year survival rates of all women's cancers and must be a priority to improve outcomes. Our passion to make a significant impact in women’s health is reflected in the hard work that has gone into this." - said Oriana Papi-Zoghbi, CEO and Co-Founder of AOA Dx.

 

Ovarian cancer is the most fatal gynecological disease for women, with over 70% of patients receiving a diagnosis at an advanced stage.  The paper reports on the quantification of tumor glycolipids as a novel tool for early detection of ovarian and other cancers. AOA’s flagship product, AKRIVIS GD, a proprietary liquid biopsy assay for early detection of ovarian cancer, has demonstrated high sensitivity and specificity to address the urgent market need.  

 

 

AOA’s novel approach to quantify tumor marker glycolipids in blood is set to help detect cancer at an early stage while it is still localized. AKRIVIS GD™ will be positioned to fulfill the urgent and unmet need for surveillance of women with early signs and symptoms of ovarian cancer in a cost-effective manner.

 

Publication is accessible here 

 

 

About AOA Dx Inc.

AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at www.aoadx.com.

Contact

Corporate Communications